ArticleTropical medicine & international health : TM & IH2026
Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023.
Article in Tropical medicine & international health : TM & IH, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Malaria in Bangladesh, 2000-2025: Navigating the Headwinds From Control to Elimination.Health science reports · 2026Article
- Molecular Markers of Antimalarial Drug Resistance in Plasmodium falciparum From Kumasi, Ghana, 2023.Tropical medicine & international health : TM & IH · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectivesArtemisinin partial resistance has emerged in East Africa and is feared to spread across the continent, potentially compromising artemisinin-based combination treatment. Molecular markers can serve as early warning signals for the development of specific drug resistance. We aimed at updating information on relevant resistance markers among Plasmodium falciparum from Kumasi, Ghana, collected in 2023.
methodsP. falciparum isolates were obtained from 200 patients with falciparum malaria. Mutations in pfk13 (propeller domain), pfcoronin (P76S), pfmdr1 (N86Y, Y184F, Y1246D) and pfaat1 (S258L) were genotyped. A subset of patients was microscopically examined for the presence of asexual malaria parasites on day-3 of treatment with artemether-lumefantrine.
results2.2% of isolates exhibited non-synonymous pfk13 mutations including the candidate artemisinin partial resistance marker P527H in addition to S522C, C532S and I590V. Pfcoronin P76S, previously associated with artemether-lumefantrine failure in malaria imported from Africa, was present in 29.7% and associated with a lower parasite density. The predominance of the pfmdr1 pattern N86-184F-D1246 (NFD) suggested impaired sensitivity to lumefantrine. Pfaat1 S258L was common at 64.7%. The resistance markers were not associated with each other, and they were not linked with day-3 parasite positivity.
conclusionsWhile the efficacy of artemisinin-based combination treatment in Ghana is still high, isolated critical pfk13 polymorphisms were identified as well as a considerable prevalence of a potentially relevant pfcoronin marker, against a background of pfmdr1 signals for impaired lumefantrine sensitivity. Continuous molecular monitoring is necessary to detect threats to artemisinin-based combination treatment efficacy at an early stage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.